Abstract
An in-situ forming implant of buprenorphine was prepared by combining PLGA RG756s and PLGA RG504H copolymers, and additives that decreased the initial burst release. The optimum formulation was achieved based on a minimum initial burst release of BP in the in-vitro release medium using a Box-Behnken design. The in-vitro, ex-vivo, and in-vivo release of the optimized formulation was investigated. The rabbit-blood concentrations of the optimized formulation and RBP-6000 (PLGA 504H) were compared to ensure their equivalency. The results indicate that the optimized formulation can reach an effective therapeutic concentration for treating opioid dependence with minimum initial burst release.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Polymeric Materials and Polymeric Biomaterials
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
